• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
186757 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
; ?: h5 f, d1 H- h! }7 C+ m' M9 {
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  - o4 \2 i. W& W! p  O; C' S
; J* \* _. \& F
8 L% ^" |' ~& {6 C; t
Sub-category:" t9 _4 g+ P0 Y% @6 P! E
Molecular Targets
# Q0 L) v) G2 ]  l
& y8 v  p, [( J! g9 ^# N- Q$ {: x4 \
Category:
; p) G0 @- ?9 kTumor Biology 0 X$ M# I% j4 j& H8 c$ |6 j- }
( R, i; l3 k% i! O9 K- h
0 y, E9 b' C  L& p6 @' j/ P& B
Meeting:
/ ]1 c! e3 M9 [+ [% P/ f2 B$ Y2011 ASCO Annual Meeting   m6 W+ M9 m0 ^; ?1 P

( ?/ P) q5 Z5 t9 x- m# }/ {1 S8 s) A0 U6 Q! L& ]* O: G
Session Type and Session Title:" o8 X, H- |( s$ M0 v
Poster Discussion Session, Tumor Biology
3 B  N3 \# u" x, B0 I* s4 I
% D: U7 a8 A9 A0 }) z5 Z! X9 {
7 G9 U' Q( c4 B4 v4 J" dAbstract No:6 N& G5 T2 s/ I; \3 n& O" G
10517
( M, ]& F! \0 E- _1 O6 Z2 K, c
, A- k5 K$ D5 X
% H; x  Q9 ]5 A2 s  ^Citation:
) ~( u# I. N" |1 {+ {J Clin Oncol 29: 2011 (suppl; abstr 10517)
- M" m* ~) `" l5 a4 G" ^5 o( u4 k7 J( X2 ?! a" z' G
. l4 Y1 N6 |( d/ n0 Z3 }
Author(s):% G1 ^0 x7 ^1 U4 o. D
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 b  e& E- p$ U# ^5 f% s6 R4 n6 R6 `. i/ p
0 H: p$ X7 j# M& Q
7 P# z6 A+ X) U0 c
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
3 Q1 ^) g1 z$ E% m" h9 y8 a
! q1 Z- d, [$ l6 B8 T/ DAbstract Disclosures
* s; S* c4 ^& l$ Y  q# `7 }8 G& K
7 C& P2 \* c3 m$ X7 h: HAbstract:( K6 {: d) N& n( O4 z+ Q( `' e
9 y2 {2 n) E) p: d2 J; l4 e, k

& _% ?8 [6 ~& e9 iBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.. o- W& |2 i; c* I7 D% d/ ~
& V* M# t/ [2 p  n" y4 Y; B# L

$ L; ]' `8 U! o7 m! V$ S
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 4 W* j% e. x. S9 p
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

; M7 I# G0 D1 j3 b( [/ k: Y2 L$ [) e化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
8 I1 h: i: R  |8 m# `易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。: ?+ P) b; j) _
ALK一个指标医院要900多 ...
9 F8 l1 q: Y- `1 ?! _2 b# C
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
0 ?2 C6 f, x4 `+ h$ e2 D+ ]2 s' n0 h' ]8 F) R
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表